Antithrombotic and Fibrinolytics Flashcards

1
Q

Anti-coagulants drugs

A
  • Prevents thrombus formation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Anti-platelet drugs

A

Prevents platelet aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Fibrinolytics

A
  • Clot retraction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Warfarin

A
  • Vitamin K antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Apixaban, Edoxaban and Rivaroxaban

A
  • Direct oral anticoagulant and reversible factor Xa
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Dabigatran

A
  • Reversible inhibitor of thrombin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Function of Warfarin

A
  • Coagulation factor (II, VII, IX, X) undergoes y - carboxylation to get activated
  • y-carboxylation requires the reduced vitamin K which is converted into oxidized vit K
  • Vitamin K reductase enzyme inhibit by Warfarin restores the reduced vitamin K
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Warfarin characteristics

A
  • Slow onset
  • Inhibit vit K-dependent protein C which is natural anti-coagulant causing pro-coagulant before anticoagulant effect
  • Excess administration can overcome warfarin binding to reductase enzyme
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pharmacokinetics of Warfarin

A
  • 99% bound to plasma albumin also metabolized in liver eliminated in urine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Drug interaction of Warfarin

A
  • Warfarin causes breakdown antibiotics and azoles which and H2 receptor antagonist
  • NSAIDs potentiate the effect of warfarin
  • Antibiotics kill gut flora and vit K increase effect of warfarin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Dabigatran

A
  • Reversible inhibitor of free thrombin
  • Fibrin-bound thrombin and thrombin induced platelet aggregation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Apixaban

A
  • Direct and reversible inhibitors of factor Xa
  • Inhibition prevent thrombotic process
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Heparin

A
  • Anti-thrombin and heparin complex bind inhibit thrombin mediated platelet activation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Externally administered Heparin

A
  • Unfractionated heparin larger molecule and low molecular weight heparin both replicate effect of normal heparin
  • Inhibitor factors of Xa (compliment anti-coagulant effect)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Adverse effects of Heparin : Hemorrhage

A
  • Caused when there is low levels of unfractionated or low MW heparin
  • Reverse effects by using protamine sulphate reverse low MW
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Heparin induced thrombocytopenia

A
  • Immune mediated low levels of thrombosis
  • Reduction of platelet count
  • Give danaparoid anticoagulant more affinity to factor Xa
16
Q

Hyperkalemia from heparin

A
  • Inhibition of aldosterone secretion by unfractionated or low MW heparin
  • Patients with diabetes chronic renal failure raised potassium levels more susceptible
17
Q

Argatroban

A
  • Direct thrombin inhibitor used in hospital
18
Q

Epopresentol

A
  • Prostacyclin inhibits platelet aggregation during renal analysis
19
Q

Fibrinolytics

A
  • Plasminogen plasma protein trapped in clot
  • Plasmin digest fibrin dissolution of clot
  • Mediated by TPA (Tissue plasminogen activator)
19
Q

Streptokinase

A
  • Natural bacterial toxin patient develops antibodies against toxin
  • Produces anaphylactic reactions
  • Replaced by TPA (Alteplase)
20
Q

ADP receptor antagonist

A
  • Clopidogrel a prodrug irreversibly inhibits ATP binding to P2Y12 reducing platelet aggregation
21
Q

Ticagrelor

A
  • Directly acts on P2Y12 and reversibly inhibits P2Y12
  • Reduction of ADP mediated platelet aggregation non-competitive
21
Q

Clopidogrel therapy

A
  • Prodrug that needs to be metabolised by CYP2C19 to be activated
  • Those carrying genetic variation may have low level CYP2C19 cannot metabolise
22
Q

Aspirin

A
  • NSAID blocks COX pathways inhibits prostaglandin release and platelet mediated prostacyclin release and platelet mediated thromboxane decrease platelet aggregation
23
Q

Glycoprotein IIb/IIIa inhibitors

A
  • Prevent platelet aggregation by blocking the binding of fibrinogen to receptors on platelets
24
Q

Abciximab

A
  • Monoclonal antibody which binds to
    glycoprotein IIb/IIIa receptors
  • Added to aspirin and heparin to prevent ischemia complications for patients undergoing coronary intervention
25
Q

Eptifibatide and tirofiban

A
  • Used to prevent early MI for patients with angina unstable